View the accessible transcript of this podcast
Thomas Jaki, Professor in Statistics at Lancaster University talks to Professor Allan Gaw about the AGILE platform trial which specifically looks at novel (new) treatments for COVID19, as opposed to repurposed treatments.
Professor Jaki describes how the efficient platform approach enables investigating treatment benefit (efficacy) and dosage in parallel and explains why AGILE is a stellar example of cross-sector collaboration. He also looks to the future: "we're hoping that the learnings from AGILE is going to lead to a much better, much faster, setting up of studies and a much more efficient way to undertake treatment development in the future."
This podcast is part of our 'Perspectives from the Pandemic' series looking at the delivery of Complex and Innovative Design (CID) trials in the COVID-19 pandemic. You can access the full series of #ComplexInnovativeDesign trial podcasts on our website: www.nihr.ac.uk/documents/delivering-complex-and-innovative-trials-podcast-collection/29517
To find out more about how the NIHR supports complex and innovative design trials, visit: www.nihr.ac.uk/innovative-trials
